Reversal of left ventricular hypertrophy with sacubitril/valsartan vs. standard antihypertensive agents in hypertension: a systematic review and network meta-analysis.

Front Cardiovasc Med · 2026 · PMC13121351 · PMID 42058496

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although Sac/Val was numerically superior to all comparators, the differences compared with enalapril and olmesartan did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.